SPIKEVAX

PreclinicalCompleted

0 views this week 0 watching

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Maternal Outcomes, Infant Outcomes, Pregnancy

Conditions

Maternal Outcomes, Infant Outcomes, Pregnancy

Trial Timeline

Mar 1, 2023 → Oct 20, 2023

NCT ID

NCT06369272

About SPIKEVAX

SPIKEVAX is a preclinical stage product being developed by Moderna for Maternal Outcomes, Infant Outcomes, Pregnancy. The current trial status is completed. This product is registered under clinical trial identifier NCT06369272. Target conditions include Maternal Outcomes, Infant Outcomes, Pregnancy.

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06130345	Preclinical	Completed	Apr 14, 2023	Feb 29, 2024	SARS-CoV-2
NCT06369272	Preclinical	Completed	Mar 1, 2023	Oct 20, 2023	Maternal Outcomes, Infant Outcomes, Pregnancy
NCT06189053	Preclinical	Active	Apr 30, 2022	Oct 31, 2027	Myocarditis

Competing Products

2 competing products in Maternal Outcomes, Infant Outcomes, Pregnancy

See all competitors

Product	Company	Stage	Hype Score
Epidiolex	Jazz Pharmaceuticals	Pre-clinical	30
Pegvaliase	BioMarin Pharmaceutical	Pre-clinical	30